Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer

Diaz, 2014, Liquid biopsies: genotyping circulating tumor DNA, J Clin Oncol, 32, 579, 10.1200/JCO.2012.45.2011 Tie, 2015, Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann Oncol, 26, 1715, 10.1093/annonc/mdv177 Budinska, 2013, Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer, J Pathol, 231, 63, 10.1002/path.4212 De Sousa, 2013, Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions, Nat Med, 19, 614, 10.1038/nm.3174 Marisa, 2013, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, 10, e1001453, 10.1371/journal.pmed.1001453 Roepman, 2014, Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, 134, 552, 10.1002/ijc.28387 Sadanandam, 2013, A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, 19, 619, 10.1038/nm.3175 2012, Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 Toyota, 1999, CpG island methylator phenotype in colorectal cancer, Proc Natl Acad Sci U S A, 96, 8681, 10.1073/pnas.96.15.8681 Weisenberger, 2006, CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, Nat Genet, 38, 787, 10.1038/ng1834 Hawkins, 2002, CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability, Gastroenterology, 122, 1376, 10.1053/gast.2002.32997 Ogino, 2007, Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample, J Mol Diagn, 9, 305, 10.2353/jmoldx.2007.060170 Domingo, 2004, Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation, Genes Chromosomes Cancer, 39, 138, 10.1002/gcc.10310 Sinicrope, 2015, Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes, Gastroenterology, 148, 88, 10.1053/j.gastro.2014.09.041 Sinicrope, 2012, Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications, Clin Cancer Res, 18, 1506, 10.1158/1078-0432.CCR-11-1469 Douillard, 2013, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer, N Engl J Med, 369, 1023, 10.1056/NEJMoa1305275 Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1065, 10.1016/S1470-2045(14)70330-4 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Fakih, 2015, Biologic therapies in colorectal cancer: indications and contraindications, Am Soc Clin Oncol Educ Book, 35, e197, 10.14694/EdBook_AM.2015.35.e197 Alberts, 2012, Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, 307, 1383, 10.1001/jama.2012.385 Allegra, 2013, Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial, J Clin Oncol, 31, 359, 10.1200/JCO.2012.44.4711 Taieb, 2014, Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial, Lancet Oncol, 15, 862, 10.1016/S1470-2045(14)70227-X Bokemeyer, 2011, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Ann Oncol, 22, 1535, 10.1093/annonc/mdq632 De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3 Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 Hutchins, 2011, Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer, J Clin Oncol, 29, 1261, 10.1200/JCO.2010.30.1366 Mouradov, 2013, Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations, Am J Gastroenterol, 108, 1785, 10.1038/ajg.2013.292 Blons, 2014, Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Ann Oncol, 25, 2378, 10.1093/annonc/mdu464 Yoon, 2014, KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance), Clin Cancer Res, 20, 3033, 10.1158/1078-0432.CCR-13-3140 Sinicrope, 2015, Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance), Clin Cancer Res, 21, 5294, 10.1158/1078-0432.CCR-15-0527 Rajagopalan, 2002, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status, Nature, 418, 934, 10.1038/418934a Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193 Tveit, 2012, Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study, J Clin Oncol, 30, 1755, 10.1200/JCO.2011.38.0915 Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019 Gavin, 2012, Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value, Clin Cancer Res, 18, 6531, 10.1158/1078-0432.CCR-12-0605 Ogino, 2012, Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, Clin Cancer Res, 18, 890, 10.1158/1078-0432.CCR-11-2246 McArthur, 2014, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol, 15, 323, 10.1016/S1470-2045(14)70012-9 Kopetz, 2009, Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, J Clin Oncol, 27, 3677, 10.1200/JCO.2008.20.5278 Lito, 2012, Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas, Cancer Cell, 22, 668, 10.1016/j.ccr.2012.10.009 Yaeger, 2015, Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients, Clin Cancer Res, 21, 1313, 10.1158/1078-0432.CCR-14-2779 Corcoran, 2015, Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer, J Clin Oncol, 33, 4023, 10.1200/JCO.2015.63.2471 Ribic, 2003, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, 349, 247, 10.1056/NEJMoa022289 Sinicrope, 2011, DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy, J Natl Cancer Inst, 103, 863, 10.1093/jnci/djr153 Klingbiel, 2015, Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, Ann Oncol, 26, 126, 10.1093/annonc/mdu499 Sargent, 2010, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 28, 3219, 10.1200/JCO.2009.27.1825 Sargent, 2014, Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database, J Clin Oncol, 32, 3507, 10.1200/jco.2014.32.15_suppl.3507 Zaanan, 2015, Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials, J Clin Oncol, 33, 3506, 10.1200/jco.2015.33.15_suppl.3506 Juo, 2014, Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis, Ann Oncol, 25, 2314, 10.1093/annonc/mdu149 Phipps, 2015, Association between molecular subtypes of colorectal cancer and patient survival, Gastroenterology, 148, 77, 10.1053/j.gastro.2014.09.038 Levine, 2016, Clinicopathological risk factor distributions for MLH1 promoter region methylation in CIMP positive tumors, Cancer Epidemiol Biomarkers Prev, 25, 68, 10.1158/1055-9965.EPI-15-0935 Schwitalle, 2008, Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers, Gastroenterology, 134, 988, 10.1053/j.gastro.2008.01.015 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov, 5, 43, 10.1158/2159-8290.CD-14-0863 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Koopman, 2009, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer, 100, 266, 10.1038/sj.bjc.6604867 Guinney, 2015, The consensus molecular subtypes of colorectal cancer, Nat Med, 21, 1350, 10.1038/nm.3967 Andre, 2015, Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC Study, J Clin Oncol, 33, 4176, 10.1200/JCO.2015.63.4238